Application of imidazole propionic acid as biomarker for predicting diabetic nephropathy and detection kit

Abstract

The invention provides application of imidazole propionic acid as a biomarker in preparation of a kit for predicting diabetic nephropathy and a related detection kit. The biomarker can be effectively used as an early diagnosis marker for predicting diabetic nephropathy, and has the advantages of accuracy, early stage and high precision.

Description

technical field [0001] The invention relates to the field of diagnosis, and more specifically relates to the application of imidazole propionic acid as a biomarker for predicting diabetic nephropathy and a detection kit comprising imidazole propionic acid as a biomarker. Background technique [0002] Diabetic kidney disease (DKD) is one of the main complications of diabetes, and it is one of the main causes of exacerbation and even death in diabetic patients. According to statistics, about 25% to 40% of diabetic patients are complicated with DKD. Although the hypoglycemic treatment of diabetes has controlled the proportion of concurrent DKD for a certain period of time, the incidence of DKD continues to rise due to the sharp increase in the incidence of diabetes year by year, the low early screening rate of complications and unsatisfactory treatment. [0003] DKD is a progressive disease. Microalbuminuria (30-300 mg) can be detected clinically in the early stage, and later ...

AI Technical Summary

Problems solved by technology

However, the downside of these diagnoses is the lack of early detection of the condition

[0004] Therefore, there is currently a lack of effective early diagnostic indicators for DKD clinically, and timely treatment cannot be given before the renal function is severely damaged to slow down the course of the disease.

Images